TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34676656
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) applied twice a week for six consecutive weeks in addition to standard wound care
Study: 32450497
Drug: brexpiprazole 2
Normalized name: brexpiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 2 or 4 mg/day
Study: 36192924
Drug: Chinese Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Medical Nutrition Therapy (CMNT) diet for T2D patients (5-day low-calorie diet followed by 10 days of habitual eating for 90 days)
Study: 36192924
Drug: Chinese Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Medical Nutrition Therapy (CMNT) diet for db/db mice (low-calorie mouse CMNT diet in day 1-4 and ad libitum regular chow for up to 7 days per cycle)
Study: 36398423
Drug: Dexmedetomidine/remifentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine/remifentanil and low dose sevoflurane anaesthesia
Study: 33792111
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn cream
Study: 38576178
Drug: BRV 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 50 mg/day
Study: 36256638
Drug: Counseling message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling message addressing user-centered concerns about self-injection (treatment group)
Study: 33369937
Drug: NOV03 4
Normalized name: NOV03
DrugBank: Perfluorohexyloctane (DB17823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOV03 4 times daily (QID)
Study: 33369937
Drug: NOV03 twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOV03 twice daily (BID)
Study: 34369566
Drug: Light force
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light force (300 g)
Study: 34369566
Drug: Heavy force
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy force (500 g)
Study: 32916236
Drug: Photon radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photon radiation with chemotherapy
Study: 32916236
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation with chemotherapy
Study: 33122694
Drug: M. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. officinalis extract containing 500 mg of rosmarinic acid (RA) daily
Study: 39437217
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Placebo
Study: 36202695
Drug: CDT or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDT or concurrent care
Study: 34058616
Drug: Associations between
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associations between clinical presentation and daily life impact
Study: 34747997
Drug: Personalized and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized and interactive messages three times a week for 2 weeks; then daily for 2 weeks
Study: 35246089
Drug: HAP‐peptide suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAP‐peptide suspension with NaOCl pre‐treatment (6.25 wt% HAP and 5 ml P11‐4 peptide, NaOCl 3%)
Study: 35246089
Drug: P11‐4 peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: P11‐4 peptide (5 ml)
Study: 33165879
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of lidocaine
Study: 33165879
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg of lidocaine
Study: 35210504
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MG)
Study: 35038429
Drug: Sugemalimab 1200
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab 1200 mg intravenously every 3 weeks for up to 24 months
Study: 33677616
Drug: 4 h
Normalized name: Type 4 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h HDMTX infusion (12 g/m2)
Study: 33677616
Drug: 12 h
Normalized name: 12 Hour Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 h HDMTX infusion (12 g/m2)
Study: 33677616
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 4 h and 12 h infusions
Study: 33196744
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tissue stabilized guided subcision, microfocused ultrasound, and calcium hydroxylapatite injections
Study: 33196744
Drug: Concomitant microfocused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant microfocused ultrasound and calcium hydroxylapatite injections followed by tissue stabilized guided subcision
Study: 32066380
Drug: Treatment-as-usual vocational
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual vocational rehabilitation (TAU‐VR)
Study: 34318912
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy for 25 minutes, two times (at 1-hour interval)
Study: 34318912
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy for 25 minutes, two times (at 1-hour interval)
Study: 34318912
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heat or cold therapy)
Study: 35488192
Drug: Sufentanil (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.35 µg/kg)
Study: 35488192
Drug: Fentanyl (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (3.5 µg/kg)
Study: 34128721
Drug: DECTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DECTA with 300 mg of iodine per kilogram by using an optimized threshold
Study: 34128721
Drug: Conventional DECTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional DECTA with 300 mg of iodine per kilogram using a conventional threshold
Study: 34128721
Drug: SECTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SECTA with standard iodine dose (600 mg of iodine per kilogram)
Study: 37721178
Drug: Glycine diet
Normalized name: gamma-Glutamyl-S-(benzyl)-cysteinyl-R(-)-phenylglycine diethyl ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine diet (30 g glycine per 1 kg meat)
Study: 34450475
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2 every 3 weeks)
Study: 34450475
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg/day) or Enzalutamide (160 mg/day)
Study: 37492920
Drug: Ligelizumab 24
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligelizumab 24 mg
Study: 36440464
Drug: Ligelizumab 72
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligelizumab 72 mg
Study: 36440464
Drug: Ligelizumab 240
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligelizumab 240 mg
Study: 33165503
Drug: Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Dose (MD) of the vaccine
Study: 33165503
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) of the vaccine
Study: 33165503
Drug: Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Dose (MD) of the vaccine with 28 days interval
Study: 33165503
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) of the vaccine with 28 days interval
Study: 32922524
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac diethylamine 2.32% w/w gel, applied every 12 hours for 7 days before surgery
Study: 32922524
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, applied every 12 hours for 7 days before surgery
Study: 35597980
Drug: rhPTX-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rhPTX-2 treatment (10 mg/kg intravenous infusions on Days 1, 3, and 5 in the first week of each 28-week cycle, then one infusion every 4 weeks up to Week 128)
Study: 35597980
Drug: rhPTX-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rhPTX-2 treatment
Study: 33045376
Drug: Single triangle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single triangle frontalis suspension using ePTFE suture
Study: 33045376
Drug: Fox pentagon
Normalized name: meadow foxtail pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fox pentagon frontalis suspension using ePTFE suture
Study: 36265942
Drug: Low-dose Paclitaxel-Coated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Paclitaxel-Coated Balloon (Ranger)
Study: 36265942
Drug: High-dose Paclitaxel-Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Paclitaxel-Coated Balloon (IN.PACT)
Study: 32785210
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rosuvastatin
Study: 35943745
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.1 mg/kg)
Study: 32487131
Drug: Dietary plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary plant sterols (PS) intervention: 2 daily portions of margarine providing 1 g PS each (2.0 g/day total) for 4 weeks.
Study: 32487131
Drug: Placebo treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment: Identical margarine containing no added PS for 4 weeks.
Study: 33739797
Drug: Sequential embryo
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential embryo transfer on days 3 and 5
Study: 33591115
Drug: NO‐NPO group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO‐NPO group (400 mL carbohydrate drink at midnight and freely up to 2 hours before anesthesia)
Study: 33734121
Drug: Valsartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine combination (n=29)
Study: 33734121
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS monotherapy (n=34)
Study: 33087779
Drug: Se‐NPs (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (5 mg kg‐1)
Study: 33087779
Drug: Se‐NPs (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (10 mg kg‐1)
Study: 33087779
Drug: Se‐NPs (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (15 mg kg‐1)
Study: 33087779
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0 mg kg‐1 Se‐NPs + 0 mg kg‐1 RF)
Study: 35998848
Drug: Selective endothelin-A
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin-A receptor antagonism
Study: 35998848
Drug: Dual endothelin-A/B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual endothelin-A/B receptor blockade
Study: 33166791
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and ipilimumab (aPD‐1/aCTLA‐4) combination treatment
Study: 33166791
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (aPD‐1)
Study: 32997182
Drug: Positive low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Positive low-dose computed tomography (LDCT)
Study: 32997182
Drug: Indeterminate low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indeterminate low-dose computed tomography (LDCT)
Study: 32997182
Drug: Negative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Negative low-dose computed tomography (LDCT)
Study: 34188004
Drug: Telmisartan, Ramipril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan, Ramipril, and their combination (exact dosages not specified)
Study: 32388622
Drug: Oxytocin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (40 IU intranasal)
Study: 33462883
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or carboplatin (AUC 6 mg/mL/min)
Study: 33462883
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (PP arm)
Study: 33462883
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus pemetrexed and platinum-based chemotherapy
Study: 34728531
Drug: sitagliptin/metformin, insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin/metformin, insulin glargine and lifestyle therapy
Study: 36188531
Drug: Light-sedation (L-Group)
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-sedation (L-Group) with bispectral index values kept in the range of 50–59
Study: 36188531
Drug: Light-sedation (L-Group)
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-sedation (L-Group)
Study: 32354052
Drug: ICT-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICT-based health management services including respiratory and urinary care devices and home visit occupational therapy
Study: 616864714
Drug: Albumin-bound paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel (260 mg/m²) combined with pirarubicin (75 mg/m²)
Study: 616864714
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) combined with pirarubicin (75 mg/m²)
Study: 35614875
Drug: P2X3-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: P2X3-receptor antagonist gefapixant
Study: 34617561
Drug: FODMAPs (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FODMAPs (50 g/d)
Study: 34617561
Drug: Gluten (17.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (17.3 g/d)
Study: 34616618
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of copra meal hydrolysate (CMH)
Study: 34616618
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of copra meal hydrolysate (CMH)
Study: 33957621
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg twice daily
Study: 34172486
Drug: Whole-school sensitisation
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-school sensitisation (teacher-meetings and whole-school activities) (CC)
Study: 35925755
Drug: Early diagnosis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early diagnosis and rapid treatment allocation
Study: 35413774
Drug: ACN-rich infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACN-rich infusion from aronia fruit (ARO)
Study: 33829274
Drug: psychoeducation/cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychoeducation/cognitive behavioural therapy
Study: 33829274
Drug: randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized treatment
Study: 33829274
Drug: waiting more
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: waiting more than 4 months before starting treatment
Study: 32247522
Drug: Perineural administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural administration of 40‐mg ketamine plus 0.375% ropivacaine in 40‐mL volume (Group RNK)
Study: 32247522
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 0.375% ropivacaine plus IV ketamine 40 mg (Group RIK)
Study: 32247522
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 0.375% ropivacaine (Group R)
Study: 36173235
Drug: BP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP with fast-acting insulin aspart (BP-F), N=114
Study: 36173235
Drug: BP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP with standard care insulin delivery (SC), N=54
Study: 36173235
Drug: BP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP with aspart or lispro (BP-A/L), N=107
Study: 33792623
Drug: Tislelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1)
Study: 33792623
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin
Study: 39004848
Drug: Anti-psychotic medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-psychotic medications
Study: 34175638
Drug: SAPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAPB with 30 ml of 0.5% ropivacaine
Study: 36436481
Drug: Zafirlukast 10
Normalized name: zafirlukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 10 mg BD for 10 days plus standard care
Study: 33221027
Drug: Silexan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 80 mg
Study: 33221027
Drug: Silexan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 80 mg/d (multiple dosing for 7 days)
Study: 33221027
Drug: Silexan 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 160 mg
Study: 33221027
Drug: Silexan 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 320 mg
Study: 33591469
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous ZOL every 3 weeks for 1 year (17 total doses)
Study: 35359478
Drug: Bilateral nasociliary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral nasociliary and maxillary nerve blocks with 12 mL of equal volumes of 0.5% bupivacaine and 2% lignocaine after induction of general anaesthesia
Study: 36263451
Drug: Daily emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emollient plus standard skin‐care advice
Study: 33880760
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg orally alone
Study: 33880760
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg i.v. infusion
Study: 34514890
Drug: Goal-Focused Emotion-Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal-Focused Emotion-Regulation Therapy (GET)
Study: 34514890
Drug: Individual Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Supportive Therapy (ISP)
Study: 36107179
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + homeopathic protocol
Study: 34941168
Drug: Ultrasound-guided quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided quadratus lumborum block (QLB) with 20 mL of 0.25% ropivacaine on each side
Study: 32111521
Drug: Brazil nut
Normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nut supplementation (one unit daily for 3 months)
Study: 34774185
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg over 4 days)
Study: 33217092
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor (SGLT2i)
Study: 33685306
Drug: Glucocorticoid (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (GC) injection
Study: 33130890
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) chemotherapy
Study: 39111544
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) therapy
Study: 32846806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NHF therapy)
Study: 35137345
Drug: Ovitrelle® (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovitrelle® (250 µg; 6500 IU)
Study: 33333105
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake ≥232 mg/day
Study: 33333105
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake >480 mg/day
Study: 33333105
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake ≥321 mg/day
Study: 35039263
Drug: Kangfuyan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuyan capsule combined with antibiotics (azithromycin + metronidazole)
Study: 35039263
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (azithromycin + metronidazole) alone (control group)
Study: 32130164
Drug: Medication Ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Ambient Display (MAD)
Study: 34475873
Drug: Nasal Foralumab
Normalized name: Foralumab
DrugBank: Foralumab (DB16170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Foralumab (100ug/day) given for 10 consecutive days with 6 mg dexamethasone given on days 1-3 (n=11)
Study: 34475873
Drug: Foralumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foralumab treatment
Study: 32933953
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment for insomnia (CBT‐I) for 8 weeks plus 4 bimonthly booster sessions